Pacira BioSciences Announces New Product-Specific J-Code For EXPAREL Effective January 1, 2025
Portfolio Pulse from Benzinga Newsdesk
Pacira BioSciences announced that the Centers for Medicare and Medicaid Services has issued a new J-code for EXPAREL, effective January 1, 2025. This change is expected to streamline billing and reimbursement processes.
October 03, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pacira BioSciences has received a new J-code for its product EXPAREL, effective January 1, 2025, which is expected to streamline billing and reimbursement processes. This could enhance the product's marketability and adoption in outpatient and office-based settings.
The new J-code for EXPAREL is significant as it standardizes billing and reimbursement, potentially increasing the product's use in outpatient and office-based settings. This regulatory change is likely to positively impact Pacira's revenue and market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100